Thrombolysis Protocol
Thrombolysis Protocol - Related Videos
05:52
Prehospital Thrombolysis: A Manual from Berlin
0 Views •
Cited by 23 •
2013
Identification of suspected stroke in the dispatch center of the Berlin Fire Brigade prompts the deployment of a CT-equipped ambulance. If ischemic stroke is confirmed and contraindications are excluded prehospital thrombolysis is applied.
06:38
The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
0 Views •
2025
To simulate thromboembolic stroke, emboli prepared from heterologous rat blood were injected into the middle cerebral artery, followed by administration of systemic thrombolysis for recanalization. This version of the model is optimized for use in a multi-laboratory network and supports testing multiple candidate therapeutics.
06:16
Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
0 Views •
2024
In-vitro thrombolysis assays have often struggled to replicate in-vivo conditions whether in the model thrombus being digested or in the environment in which thrombolysis is occurring. Herein, we explore how coupling the Chandler loop and Real-Time Fluorometric Flowing Fibrinolysis Assay (RT-FluFF) is used for high-fidelity, ex-vivo, clot lysis monitoring.
07:12
Neutrophil Isolation Protocol
0 Views •
Cited by 176 •
2008
Neutrophils are among the first cells to arrive on the site of inflammatory immune response, and their functions and mechanisms have been studied extensively in vitro. We demonstrate a standard density gradient separation method to isolate human neutrophils from whole blood using commercially available separation media.
07:56
Parabiosis in Mice: A Detailed Protocol
0 Views •
Cited by 188 •
2013
Parabiotic joining of two organisms leads to the development of a shared circulatory system. In this protocol, we describe the surgical steps to form a parabiotic connection between a wild-type mouse and a constitutive GFP-expressing mouse.
FAQs
Tissue plasminogen activator initiates conversion of plasminogen into plasmin. Plasmin then attacks fibrin, the structural protein holding the clot together. As fibrin is degraded, the obstruction can loosen or dissolve, allowing blood flow to return through the affected vessel. This molecular sequence explains the protocol’s clot-dissolving action.
Rapid implementation is intended to preserve brain tissue that remains threatened by reduced circulation. The protocol links prompt assessment and treatment decisions with the possibility of restoring flow before ischemic injury becomes more extensive. Its neurological significance is therefore time-sensitive: faster progression through evaluation and treatment may help limit neuronal damage and support better functional recovery.
Eligibility screening is the point at which expected benefit is balanced against the possibility of bleeding. A patient may have threatened brain tissue that could benefit from restored circulation, yet clot-dissolving treatment also carries hemorrhagic risk. The protocol therefore does not treat vessel reopening as the only goal; it uses careful selection to determine whether potential neurological benefit justifies treatment.
Brain imaging is a central decision-making component within the protocol because clinicians use it alongside patient assessment and eligibility screening when evaluating treatment suitability. Imaging helps guide the treatment decision rather than leaving it to symptoms alone. In acute ischemic stroke care, this step supports more careful selection before clot-dissolving medication is administered.
Core stages include rapid patient assessment, brain imaging, eligibility screening, medication administration, and subsequent monitoring. The sequence is structured so clinicians first characterize the acute event and determine whether treatment is appropriate, then deliver the clot-dissolving medication and observe the patient for complications. This workflow connects urgent intervention with safety checks and neurological observation.
Bleeding is the key complication identified in the protocol, making monitoring essential after medication is given. Clinical teams must watch for complications while also considering whether circulation has been restored and whether neurological status improves. This surveillance addresses both sides of the risk-benefit equation: the intended reduction of vessel obstruction and the possibility of hemorrhagic harm.